

Announcement Summary

Entity name

ARTRYA LIMITED

Announcement Type

New announcement

Date of this announcement

12/3/2024

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Tranche 1 Options: exercise price \$0.292 and expiring 5 years from issue date	500,000
New class-code to be confirmed	Tranche 2 Options: exercise price \$0.292 and expiring 5 years from issue date	680,000

Proposed +issue date

12/3/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

ARTRYA LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ACN

624005741

1.3 ASX issuer code

AYA

1.4 The announcement is

New announcement

1.5 Date of this announcement

12/3/2024

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class

Will the proposed issue of this +security include an offer of attaching +securities? No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? No

of the 'new' class of +securities on ASX? No

ASX +security code

+Security description

New class-code to be confirmed

Tranche 1 Options: exercise price \$0.292 and expiring 5 years from issue date

+Security type

Options

Number of +securities proposed to be issued

500,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Please describe the consideration being provided for the +securities

Options issued under a commercial partnership agreement with Tanner Health System (refer ASX announcement dated 12/03/2024)

Please provide an estimate of the AUD equivalent of the consideration being



provided for the +securities

0.198000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currency **Exercise price Expiry date** AUD - Australian Dollar AUD 0.2920 12/3/2029

Details of the type of +security that will be issued if the option is exercised

AYA: ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One ordinary share to be issued for each vested and exercised option

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02783756-6A1197808

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class

Will the proposed issue of this +security include an offer of attaching +securities? No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

Have you received confirmation from Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code +Security description

New class-code to be confirmed Tranche 2 Options: exercise price \$0.292 and expiring 5 years from issue date

+Security type

Options

Number of +securities proposed to be issued

680,000

Offer price details



Are the +securities proposed to be issued being issued for a cash consideration?

Please describe the consideration being provided for the +securities

Options issued under a commercial partnership agreement with Tanner Health System (refer ASX announcement dated 12/03/2024)

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.198000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Options details

+Security currencyExercise priceExpiry dateAUD - Australian DollarAUD 0.292012/3/2029

Details of the type of +security that will be issued if the option is exercised

AYA: ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One ordinary share to be issued for each vested and exercised option

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02783756-6A1197808

Part 7C - Timetable

7C.1 Proposed +issue date

12/3/2024

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

1180000



7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

Nο

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

No

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

No other fees

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The Options are being issued under a commercial partnership agreement with Tanner Health System (refer ASX announcement dated 12/03/2024)

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

7F.2 Any other information the entity wishes to provide about the proposed issue

Tranche 1 - 500,000 options. These options vest if the vesting conditions are met by 30 August 2024.

Tranche 2 - 680,000 options. These options vest in 4 equal tranches on the 1st, 2nd, 3rd and 4th anniversary of the execution of the Commercial Agreement.